By Connor Boyd Well being And Science Editor For Dailymail.Com
21:12 15 Mar 2024, up to date 21:17 15 Mar 2024
Share or touch upon this text:
Prescriptions for a brand new and probably stronger weight reduction drug have overtaken Wegovy for the primary time.There have been 77,590 new scripts written within the US for Eli Lilly’s Zepbound through the week ending March 8 – round 6,000 greater than its rival.Nonetheless, there have been nonetheless extra total prescriptions for Wegovy when current sufferers had been factored in, in response to knowledge firm IQVIA.Lilly launched Zepbound within the US in December greater than two years after Wegovy’s approval in June 2021. Trials indicated that the previous sheds extra fats. Prescriptions for a brand new and probably stronger weight reduction drug Zepbound have overtaken Wegovy for the primary time (file) Zepbound incorporates the lively ingredient tirzepatide which works by suppressing two appetite-regulating hormones, making folks really feel fuller for longer.Wegovy, alternatively, solely acts on one hormone.Market analysts see the load loss drug business rising to at the very least $100 billion by the tip of the last decade. Information analytics agency GlobalData in a report on Friday stated GLP-1 medication are on tempo to this yr surpass most cancers immunotherapies because the best-selling medicines.Merck and Co’s most cancers drug Keytruda is presently the world’s top-selling prescription medication with over $25 billion in annual gross sales.Zepbound and Wegovy belong to a category of medicine referred to as GLP-1 agonists developed for sort 2 diabetes that additionally cut back meals cravings and trigger the abdomen to empty extra slowly.The U.S. Meals and Drug Administration final week authorized Wegovy for decreasing the chance of stroke and coronary heart assault in obese or overweight adults who do not need diabetes. GlobalData forecast the marketplace for these medicines reaching $105 billion by 2029, and that Novo Nordisk would seize greater than half of that with its portfolio of GLP-1 medication, together with Wegovy.The Danish drugmaker final week stated it was assured it could launch a tablet model of its experimental weight-loss drug amycretin this decade. At the moment GLP-1 medication are injected.Lilly’s diabetes drug Mounjaro, which has the identical lively ingredient as Zepbound, would be the top-selling GLP-1 with $33.4 billion in annual gross sales by 2029, GlobalData forecast.Lilly this week stated it has partnered with Amazon.com’s pharmacy unit to ship drug prescriptions despatched to its direct-to-consumer service LillyDirect, together with these for Zepbound.Frank Cunningham, an govt at Lilly, stated the corporate was “very happy” with the variety of prescriptions it had crammed by means of LillyDirect to this point.
Share or touch upon this text: Prescriptions for Eli Lilly’s newly-approved weight-loss drug Zepbound overtake Wegovy for the primary time – with practically 150,000 new sufferers now filling a script for the pictures every WEEK